Oncology Medical News about Sorafenib

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma
Clinical Cancer Research, 09/15/09

Ou D–L et al. – Sorafenib has proved survival benefit for patients with advanced hepatocellular carcinoma (HCC). This study explored whether the efficacy of sorafenib can be improved by adding the mitogen–activated protein kinase/extracellular signal–regulated kinase (ERK) kinase (MEK) inhibitor CI–1040 to vertically block the Raf/MEK/ERK pathway. The antitumor effects of sorafenib in HCC can be improved by vertical blockade of Raf/MEK/ERK signaling with CI–1040.

Exclusive Author Commentary
Chiun Hsu, 09/15/09

Sorafenib can prolong survival in patients with advanced hepatocellular carcinoma (HCC). We demonstrated that the therapeutic efficacy of sorafenib can be improved by combining sorafenib and the MEK inhibitor CI-1040 using in vitro and in vivo HCC models. Induction of Bim protein level, which was regulated by ERK, might contribute to the drug synergy. These data provide insight on how sorafenib works in HCC and the rationale how vertical blockade of the Raf/MEK/ERK signaling pathway may be used in future clinical trials.

<< Previous
Phosphatidylinositol 3'-Kinase Catalytic Subunit alpha Gene...

Next >>
Tramadol and Flurbiprofen Depress the Cytotoxicity of Cisplatin...

Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09 Relevance Score: 96%%

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety
Hepatology, 11/02/09 Relevance Score: 87%%

Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09 Relevance Score: 87%%

Glucose-Regulated Protein 78 Is a Novel Contributor to Acquisition of Resistance to Sorafenib in Hepatocellular Carcinoma
Annals of Surgical Oncology, 10/20/09 Relevance Score: 87%%

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
European Journal of Endocrinology, 10/06/09 Relevance Score: 87%%